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Abstract 
Background 
Small vessel disease is reported to be a more common cause of ischaemic stroke in 
people with diabetes than in others. However, population-based studies have shown 
no difference between  those with and those without diabetes in the subtypes of 
stroke.We determined the rates and predictors of risk of stroke and its subtypes in the 
FIELD trial. 
Methods 
9795 patients aged 50–75 years with type 2 diabetes were followed up for a median 
of 5 years. Annual rates were derived by the Kaplan-Meier method and independent 
predictors of risk by Cox proportional-hazards regression analyses.  
Results 
The annual rate of stroke was 6.7 per 1000 person–years; 82% were ischaemic, and 
caused by small artery disease (36%), large artery disease (17%), and embolism from 
the heart (13%); 10% were haemorrhagic. Among the strongest baseline predictors of 
ischaemic or unknown stroke were age (60–65 years, hazard ratio (HR) 1.98; >65 
years, HR 2.35) and a history of stroke or TIA (HR 2.06). Other independent baseline 
predictors were male sex, smoking, history of hypertension, ischaemic heart disease, 
nephropathy, systolic blood pressure, and blood LDL cholesterol, HbA1c, and 
fibrinogen. A history of peripheral vascular disease, low HDL, age, and history of 
hypertension were associated with large artery ischaemic stroke. A history of diabetic 
retinopathy, LDL cholesterol, male sex, systolic blood pressure, smoking, diabetes 
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duration, and a history of stroke or TIA were associated with small artery ischaemic 
stroke.  
Conclusions  
Older people with a history of stroke were at highest risk of stroke, but the prognosis 
and prognostic factors of subtypes were heterogeneous. The results will help 
clinicians quantify the absolute risk of stroke and its subtypes for typical diabetes 
patients.
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The major contributor to the burden and cost of diabetes is vascular disease of the 
brain, eye, heart, kidneys and peripheral nerves. The Emerging Risk Factors 
Collaboration’s meta-analysis indicated that a history of diabetes increased the hazard 
for ischaemic stroke and haemorrhagic stroke.[1] The hazard ratios (HRs) for 
ischaemic stroke in people with diabetes, adjusted for baseline covariates, were 
higher in women, patients aged 40–59 years, and patients with above average body 
mass index (BMI); the HRs did not change significantly after additional adjustment 
for lipids, and fasting blood glucose concentration was not linearly related to the risk 
of ischaemic stroke.[1] The annual rate of stroke in a cohort of 41 799 people with 
diabetes in the UK was 11.9 per 1000 person–years, compared with 5.5 per 1000 
person–years in 202 733 controls.[2] 
The debate over which factors increase the risk of stroke in diabetic people is 
controversial.  In the Diabetes and Informatics study of 14 432 people with type 2 
diabetes, the rate of stroke was much higher among people with a history of 
cardiovascular disease than those with no history of cardiovascular disease.[3] The 
only other consistently significant and independent prognostic factor for stroke in 
people with diabetes is age, but some studies have shown that the risk of stroke 
decreases with age beyond 35–54 years[1, 2] and others that the risk increases with 
age.[3–6] Other adverse prognostic factors reported in some, but not all, studies 
include sex, smoking, obesity, atrial fibrillation, hypertension, systolic blood pressure, 
total-to-high-density-lipoprotein (HDL) cholesterol ratio, waist circumference, 
microvascular complications, duration of diabetes, and therapy with insulin plus oral 
agents.[2–6]  
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There also is uncertainty about the frequency with which the different aetiological 
subtypes of ischaemic stroke occur in diabetes patients. Ischaemic stroke caused by 
intracranial small-vessel disease (lacunar infarction) is reported to be more common 
in diabetic people than others, presumably because of their higher prevalence of 
microvascular disease.[7–9] However, the few population based studies of incident 
cases of stroke have shown no significant difference in the subtypes of stroke 
between diabetic and nondiabetic people.[10–14] Although the Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) study[15] was not a 
population based study, it provided an opportunity to determine the rate and 
predictors of risk of stroke  in a large cohort of diabetes patients followed up over a 
long period, with outcome events systematically assessed by a panel of stroke experts. 
Our study design and data also allowed us to ascertain the risks of pathological and 
aetiological subtypes of stroke in this cohort. 
Methods 
The design and results of the FIELD study have been reported.[15,16] FIELD, a 
double blind, placebo controlled, randomised trial undertaken in 63 centres in 
Australia, New Zealand and Finland between 1998 and 2005, enrolled 9795 patients 
with type 2 diabetes mellitus. The study was designed to offer at least 80% power at 
2P=0.05 to identify as significant a 22% reduction in coronary events among patients 
assigned fenofibrate. Participants were recruited from hospital clinics and community 
based sources. All patients gave written informed consent. The study protocol was 
approved by local and national ethics committees and was undertaken in accordance 
  Hankey et al. 7 
with the Declaration of Helsinki and Good Clinical Practice guidelines. Results of 
this analysis are reported according to the STROBE guidelines (17). 
Patients were aged 50–75 years and had an initial plasma total cholesterol 
concentration of 3.0–6.5 mmol/L, plus either a total-cholesterol-to-HDL-cholesterol 
ratio of at least 4.0 or a plasma triglyceride concentration of 1.0–5.0 mmol/L. The 
study had wide inclusion criteria in order to recruit patients across an extensive range 
of characteristics with regard to age, sex, location and clinical management. 
Exclusion criteria included renal impairment (plasma creatinine >130 μmol/L), 
known chronic liver disease or symptomatic gallbladder disease, and a cardiovascular 
event within 3 months before recruitment. 
All patients were randomly allocated to once daily micronised fenofibrate 200 mg 
(n=4895) or matching placebo (n=4900) on a background of usual care. Planned 
follow-up was every 4–6 months over an average of 5 years. All the patients were 
treated according to the diabetic guidelines that were current at the time of the study. 
Decisions about changes in therapy for diabetes or comorbid conditions, including 
lipid lowering therapy, were at the discretion of the patient's primary care doctor or 
specialist physician. 
Outcomes 
The primary outcome event for this substudy was stroke and its pathological and 
aetiological subtypes. All primary outcome events (and major cardiovascular disease 
events) were adjudicated by an outcomes assessment committee, unaware of 
treatment allocation, using definitions specified before the study began. Each primary 
outcome event was adjudicated by two members of the outcomes assessment 
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committee. When there was disagreement, the event was adjudicated by the third 
member. If there was still disagreement after the third evaluation, the event was 
discussed at a meeting of the full committee. The diagnosis of stroke and its 
pathological and aetiological subtype required agreement by at least two of the 
outcomes assessment committee. 
Stroke was defined as an acute new disturbance of focal neurological function 
resulting in death or lasting more than 24 hours and thought to be due to brain 
infarction or intracranial haemorrhage.[18] Ischaemic stroke was defined as a definite 
stroke[18] in which computed tomography (CT) scans or magnetic resonance 
imaging (MRI) within three weeks of symptom onset showed an infarct in the 
clinically relevant area of the brain, or if the imaging was normal or showed a 
clinically irrelevant abnormality, or autopsy showed evidence of relevant brain 
infarction. 
Large artery ischaemic stroke was defined as a nonlacunar ischaemic stroke with 
clinical, duplex ultrasound, or angiography evidence of occlusive disease of the 
extracranial or intracranial large artery supplying the ischaemic brain, (including the 
aortic arch, common and internal carotid artery, main stem of the middle cerebral 
artery, vertebral artery, and basilar artery). In addition, there was no major 
cardioembolic source (see below), and the clinical opinion of the outcomes 
assessment committee was that the most likely cause of the brain infarct was large 
artery disease.  
Small-artery ischaemic stroke was defined as ischaemic stroke with either one of the 
classical lacunar syndromes (pure motor hemiparesis, pure hemisensory loss, pure 
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hemisensorimotor loss, ataxic hemiparesis or basilar branch artery syndrome), 
together with a CT or MRI that was normal or showed a small (<1.5 cm) infarct in the 
basal ganglia, internal capsule, or brainstem. 
Cardioembolic ischaemic stroke was defined as nonlacunar ischaemic stroke with a 
major cardioembolic source (for example, atrial fibrillation, myocardial infarction in 
the preceding 6 weeks, echocardiographic evidence of left ventricular thrombus, 
endocarditis, or a prosthetic heart valve), plus no definite evidence of large artery 
disease (see above), and clinical opinion that the most likely cause of the brain infarct 
was embolism from the heart.  
Ischaemic stroke of unknown or uncertain cause was defined as a definite ischaemic 
stroke that did not meet the above criteria, or where there was more than one possible 
explanation (for example, in a patient with atrial fibrillation and carotid stenosis). 
Haemorrhagic stroke was defined as an intracerebral or subarachnoid haemorrhage. 
Intracerebral haemorrhage was defined as a definite stroke [18] in which CT, MRI or 
autopsy showed haemorrhage into the clinically relevant area of the brain, excluding 
haemorrhagic transformation of infarction, haemorrhage into a tumour, and 
haemorrhage secondary to trauma. Subarachnoid haemorrhage was defined as a 
typical clinical syndrome of sudden onset of headache, with or without neck stiffness 
and focal neurological signs, and with CT, cerebrospinal fluid, or autopsy evidence of 
bleeding primarily in the subarachnoid space. 
Stroke of unknown pathological type was a definite stroke [18] in which there was no 
documentation of the pathological type (infarction or haemorrhage) by CT, MRI, or 
autopsy. Transient ischaemic attack (TIA) of the brain or eye was defined as an acute 
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new disturbance of focal neurological or monocular function with symptoms lasting 
less than 24 hours and thought to be due to brain or ocular ischaemia.[19] 
Cause specific mortality was classified into major categories of coronary, other 
vascular, cancer, and other noncardiovascular disease subtypes. Cardiovascular 
disease events comprised, as well as stroke, coronary heart disease death, 
cardiovascular disease death, nonfatal myocardial infarction, and coronary and 
carotid revascularisation. Major cardiovascular events were coronary death, 
cardiovascular death, and stroke. 
Statistical analysis 
Categorical baseline characteristics were analyzed with chi squared tests. For 
continuous variables, groups were compared with analysis of variance when data 
could be assumed to be normally distributed. Otherwise, the Kruskal–Wallis test was 
used. A small number of  missing values at baseline were imputed. Missing values for 
homocysteine (273) were estimated on the basis of linear regression for values of all 
other baseline variables. For other variables, the median was imputed (urinary 
albumin (27), urinary creatinine (27), albuminuria (27), diabetes duration (17), BMI 
(7), waist–hip ratio (13), fibrinogen (1)). Sex specific medians were used for BMI and 
waist-hip ratio. Ethnicity was not considered in the analysis. 
Cumulative risk curves derived by the Kaplan–Meier method were plotted. The 
average annual stroke rate was calculated according to the formula 1–((1–Ic)1/n), 
where Ic is the cumulative incidence rate at n years of follow-up. The 95% confidence 
interval for the average annual rate was obtained using the upper and lower 95% 
confidence limits of Ic instead of Ic in the above formula.[20] 
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Cox proportional hazards models were used to develop risk models for the most 
common pathological subtype of stroke (ischaemic or unknown pathological 
subtypes) and two of its aetiological subtypes (large artery and small artery disease), 
as well as for the less common pathological subtype—haemorrhagic stroke. The 
proportional hazards assumption was checked with the Harrell-Lee test.[21] All 
models were stratified on treatment allocation. All continuous variables were 
standardised by dividing them by their standard deviation. Selection of predictor 
variables used the backward elimination method. The same results were obtained 
with the exhaustive search method.[22] Discrimination was assessed with the c 
statistic, which shows the ability of the model to discriminate subjects with the 
outcome from those without the outcome. A risk of using the same data for the 
modelling process and model performance is to obtain an overoptimistic estimate of 
performance. Therefore, the optimism corrected c statistic, a nearly unbiased estimate 
of predictive accuracy, was calculated by using bootstrapping with 200 bootstrap 
samples.[23] Calibration of the risk model for total stroke was assessed by comparing 
observed and expected numbers of events in each decile of risk.[24] 
P values less than 0.05 were considered statistically significant. All analyses were by 
intention to treat and used SAS (version 9.2) or ACCorD (Analysis of Censored and 
Correlated Data) (version 1.6.3). 
Results 
Baseline characteristics and progression of diabetes 
All 9795 participants were included in the analysis (Figure 1, Table 1). Follow-up 
continued until the end of the trial at median 5.0 years (final visits from January to 
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May, 2005). Complete follow-up was achieved for 99.1% of participants; 65 were not 
evaluable for morbidity (including stroke) at study close. Over the course of the 
study, HbA1c levels remained stable from a median of 52 mmol/mol at baseline to 53 
mmol/mol at 5 years.  
Outcomes 
A total of 333 patients experienced 366 strokes during follow-up; 303 had one stroke, 
28 two, one three, and one four (Table 2). The first on-study stroke was ischaemic in 
81.4% of patients (95% CI 76.9 to 85.2%), haemorrhagic in 9.9% (95% CI 7.1 to 
13.6%), and unknown in 8.7% (95% CI 6.1 to 12.2%). The most common cause of 
ischaemic stroke was small artery disease (108 events in 101 patients, 36.1%; 95% 
CI, 30.9 to 41.7%), followed by large artery disease (52 events in 50 patients, 17.4%; 
95% CI, 13.5 to 22.1%), and embolism from the heart (38 events in 36 patients, 
12.7%; 95% CI, 9.4 to 17.0%). The other 101 events in 99 patients (33.8%; 95% CI, 
28.7 to 39.3 %) were ischaemic strokes of unknown or uncertain cause. 
The cumulative risks of first stroke, first ischaemic or unknown stroke, first small 
artery ischaemic stroke, first large artery ischaemic stroke, and first haemorrhagic 
stroke were linear over the 5 years of follow-up (Figure 2). The average annual rate 
of first stroke was 0.67% (95% CI, 0.60 to 0.75%). 
Predictors of risk of pathological subtypes of stroke 
The baseline prognostic variables that were significantly and independently 
associated with stroke of ischaemic or unknown pathological type were age, male 
sex, history of stroke or TIA, history of hypertension, history of ischaemic heart 
disease, history of nephropathy (or albumin-creatinine ratio), current smoking, higher 
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systolic blood pressure, higher LDL cholesterol, HbA1c, and fibrinogen concentration 
(Table 3). The discriminatory ability and calibration of the model were satisfactory 
(optimism adjusted c statistic of 0.72 with no statistically significant differences 
between observed and expected event counts within deciles of predicted risk (all 
P>0.10)).  
Figure 3 shows diagrammatically the effect of selected risk profiles on the predicted 
5-year absolute risk of ischaemic or unknown stroke.  
Variables independently associated with haemorrhagic stroke were age, systolic 
blood pressure, plasma total homocysteine, and history of stroke or TIA.  
Predictors of risk of aetiological subtypes of ischaemic stroke 
Variables associated with large artery ischaemic stroke were age, history of 
hypertension, history of peripheral vascular disease, and HDL concentration. 
Variables associated with small artery ischaemic stroke were male sex, systolic blood 
pressure, current smoking, history of stroke or TIA, history of diabetic retinopathy, 
LDL cholesterol concentration, and diabetes duration. 
Discussion 
The principal findings from this observational study of nearly 10 000 patients with 
diabetes enrolled in a randomised trial were, first, that stroke occurred at a reasonably 
constant rate of about 6.7 per 1000 person–years over five years of follow-up; 
second, most stroke events were ischaemic; and third, the cause of ischaemic strokes 
was most commonly small artery disease, followed by large-artery disease, and 
embolism from the heart. Independent significant baseline predictors of a stroke of 
ischaemic or unknown pathological type were male sex, age, history of hypertension, 
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ischaemic heart disease, stroke or TIA, nephropathy, current smoking, higher systolic 
blood pressure, and concentrations of LDL cholesterol, HbA1c and fibrinogen. 
Besides age, systolic blood pressure, and a history of stroke and TIA, there were 
notable differences in the baseline predictors of the pathological and aetiological 
subtypes of stroke. Male sex, a history of hypertension, ischaemic heart disease, 
nephropathy, current smoking, and concentrations of LDL cholesterol, HbA1c, and 
fibrinogen increased the hazard of ischaemic stroke, whereas plasma total 
homocysteine increased the hazard of haemorrhagic stroke. Among the subtypes of 
ischaemic stroke, a history of peripheral vascular disease and the inverse of HDL 
cholesterol concentration (as well as age and a history of hypertension) increased the 
hazard of a large artery ischaemic stroke, whereas a history of diabetic retinopathy 
and LDL cholesterol concentration (as well as male sex, higher systolic blood 
pressure, current smoking, diabetes duration and a history of stroke or TIA) increased 
the hazard of small artery ischaemic stroke. 
The strengths of this study, supporting the validity of the results, are that many 
diabetes patients, diagnosed by standardised diagnostic criteria and meeting 
predefined inclusion criteria, were prospectively assessed at baseline for relevant 
demographic, clinical and comorbidity features and followed up prospectively, 
regularly, and almost completely, for the occurrence of stroke (17,19,20). At the same 
time, patients’ diabetes was managed in the real world setting of usual clinical care. 
Stroke was diagnosed and adjudicated, blinded to treatment allocation, by a panel of 
stroke experts (GJH, NA, MR) according to standard diagnostic criteria.  
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The limitations of the study are that the patients were recruited at varying times in 
relation to onset of their disease, the diagnosis of the aetiological subtype of 
ischaemic stroke relied on clinical and imaging criteria that could not be fulfilled in 
all cases (e.g. not all participants with a stroke underwent an MRI brain scan) and are 
not always accurate, and that the results are not necessarily generalisable to diabetes 
patients younger than 50 or older than 75 years or with plasma total cholesterol 
concentrations outside the eligibility range of 3.0 to 6.5 mmol/L. Further, 22 (0.2%) 
were lost to follow-up and 65 were not evaluable for morbidity at study close.  
Our results are generally consistent with those of other studies,[1–6] but there are 
differences. First, unlike population based studies,[10–14] in this study intracranial 
small vessel disease was the major cause of stroke, as has been reported in hospital 
based studies.[7–9] The intracranial small vessel disease may be caused, to some 
extent at least, by the diabetes but could also reflect the higher prevalence of 
hypertension, or other unmeasured risk factors, among the participants with stroke. 
Second, the average annual rate of stroke of about 6.7 per 1000 person–years was 
higher than that observed among individuals with childhood-onset Type 1 DM (about 
3.0 per 1000 person-years over a mean follow-up of 15 years)  [25] but lower than in 
other cohorts of individuals with type 2 diabetes[2,3]. The prevalence of concurrent 
cardiovascular disease was similar among our cohort and other cohorts of type 2 
diabetics, but our lower stroke rate may be explained by more vigilant follow-up by 
specialist diabetes physicians inherent in a clinical trial, and the more widespread 
availability and use of evidence-based treatments to lower stroke risk, such as 
lowering blood pressure and lowering cholesterol. Third, we did not find that the risk 
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of stroke was lower beyond the age of 54 years, as suggested in some studies.[1,2] 
Rather, in accordance with other studies,[3–6] we found that increasing age was an 
independent and significant prognostic factor for each subtype of stroke, except for 
small artery ischaemic stroke. Fourth, atrial fibrillation, reported as prognostic in 
other studies[2,5] and which might be expected to be related to stroke, was significant 
in our univariable model but not in multivariable analysis, presumably because it was 
highly correlated with age, history of hypertension, prior myocardial ischaemia, 
nephropathy, HbA1c and age. Another reason for the failure of atrial fibrillation to be 
a significant independent predictor may be that cardioembolic stroke (for which atrial 
fibrillation is a risk factor) accounted for only a minority of ischaemic strokes 
(38/299; 13%); that is, cardioembolic stroke may not be as common in diabetes 
patients as other patient populations. Diabetes duration was similarly correlated with 
other factors and predicted only small artery ischaemic strokes. 
In the Emerging Risk Factors Collaboration study, the adjusted HRs for ischaemic 
stroke with diabetes were higher for women, whereas our adjusted HRs were higher 
for men.[1] Our finding may reflect the younger age of our cohort (50–75 years) and 
failure to include older diabetic patients, among whom women may be at higher risk. 
In the Emerging Risk Factors Collaboration study, these adjusted HRs did not change 
significantly after additional adjustment for lipids,[1] concurring with our results for 
all ischaemic stroke, but we found that the adjusted HRs for the aetiological subtypes 
of ischaemic stroke did change after additional adjustment for lipids; the HRs for 
large artery ischaemic stroke were significantly higher with lower HDL cholesterol 
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concentrations and the HRs for small artery ischaemic stroke were significantly 
higher with higher LDL cholesterol concentrations. 
In conclusion, patients with diabetes in this large clinical trial cohort had a 0.7% 
annual risk of stroke. Those at highest risk of stroke were older and had a history of a 
previous stroke.  Most strokes were ischaemic and most ischaemic strokes were due 
to small vessel disease. However, ischaemic large artery disease and embolism from 
the heart also accounted for a significant proportion of ischaemic strokes. This  
highlights the importance of individualised assessment and management of diabetics 
who experience a stroke. Our results will help clinicians quantify the absolute risk 
and independent significant predictors of stroke and its subtypes for typical patients 
with diabetes aged 50 to 75 years. 
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Figure legends 
Figure 1 
Enrolment and progress of FIELD patients 
 CVD, cardiovascular disease, TIA, transient ischaemic attack. 
Figure 2 
Time to first stroke 
Stroke of any type (black line), first ischaemic or unknown stroke (blue), first 
small-artery ischaemic stroke (red), first large-artery ischaemic stroke (yellow), 
and first haemorrhagic stroke (green). Average annual rates of stroke (%, 95% 
CI): any, 0.67 (0.60–0.75); ischaemic or unknown, 0.61 (0.55—0.69); small-
artery ischaemic, 0.21 (0.17–0.25); large-artery ischaemic, 0.10 (0.08–0.13); 
haemorrhagic, 0.07 (0.05– 0.10).  
Figure 3  
Typical profiles of risk 
Effect of selected risk profiles on the predicted 5-year absolute risk of ischaemic 
or unknown stroke (keeping constant: placebo, no history of hypertension; no 
prior angina or coronary artery procedure; no nephropathy; LDL cholesterol=3.0 
mmol/L, fibrinogen=3.6 g/L).  
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Table 1: Baseline characteristics of patients in relation to on-study strokes over a median of 5 years of follow-up*† 
 
 Stroke (n=333) 
Other CVD event
(n=962) 
No CVD event 
(n=8500) 
General characteristics    
Fenofibrate treatment group   158 (47.4%) 454 (47.2%) 4283 (50.4%) 
Male sex  245 (73.6%) 735 (76.4%) 5158 (60.7%) 
Age at visit 1 (years, mean(SD)) 65.2 (6.2) 64.0 (6.7) 61.9 (6.9) 
Diabetes duration (years, median(IQR)) 7 (3–12) 7 (3–12) 5 (2–9) 
Body-mass index (kg/m2, median(IQR)) 30.0 (27.2–33.5) 29.6 (26.8–33.0) 29.8 (26.8–33.6) 
Waist-to-hip ratio (mean(SD)) 0.95 (0.07) 0.95 (0.08) 0.93 (0.08) 
Smoking     
 Non smoker 115 (34.5%) 309 (32.1%) 3505 (41.2%) 
 Ex-smoker 180 (54.1%) 532 (55.3%) 4232 (49.8%) 
 Current smoker 38 (11.4%) 121 (12.6%) 763 (9.0%) 
Systolic blood pressure (mmHg, mean(SD)) 148.1 (16.3) 142.8 (15.4) 139.9 (15.2) 
Diastolic blood pressure (mmHg, mean(SD)) 84.2 (9.0) 82.0 (8.8) 81.9 (8.5) 
Clinical history    
History of hypertension  246 (73.9%) 593 (61.6%) 4707 (55.4%) 
Heart rate (bpm, mean(SD)) 72.2 (9.7) 72.6 (9.6) 72.4 (8.8) 
Atrial fibrillation  17 (5.1%) 37 (3.8%) 145 (1.7%) 
Prior myocardial infarction  32 (9.6%) 146 (15.2%) 307 (3.6%) 
Prior angina, PTCA or CABG  92 (27.6%) 270 (28.1%) 923 (10.9%) 
Prior stroke  34 (10.2%) 49 (5.1%) 264 (3.1%) 
Prior TIA  33 (9.9%) 44 (4.6%) 230 (2.7%) 
History of diabetic retinopathy  50 (15.0%) 128 (13.3%) 636 (7.5%) 
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 Stroke (n=333) 
Other CVD event
(n=962) 
No CVD event 
(n=8500) 
Neuropathy (self-reported or monofilament test)  83 (24.9%) 254 (26.4%) 1354 (15.9%) 
Nephropathy (self-reported or ACR measurement)  140 (42.0%) 363 (37.7%) 2095 (24.6%) 
Amputation (microvascular)  1 (0.3%) 1 (0.1%) 16 (0.2%) 
Peripheral vascular disease  44 (13.2%) 148 (15.4%) 573 (6.7%) 
Metabolic syndrome  289 (86.8%) 826 (85.9%) 6986 (82.2%) 
Laboratory data    
Urine albumin-creatinine ratio ‡    
 Normal 197 (59.2%) 608 (63.2%) 6482 (76.3%) 
 Microalbuminuria 106 (31.8%) 276 (28.7%) 1722 (20.3%) 
 Macroalbuminuria 30 (9.0%) 78 (8.1%) 296 (3.5%) 
Total cholesterol (mmol/L, mean (SD)) 5.06 (0.71) 5.08 (0.68) 5.03 (0.71) 
LDL cholesterol (mmol/L, mean (SD)) 3.10 (0.64) 3.13 (0.63) 3.06 (0.65) 
HDL cholesterol (mmol/L, mean (SD)) 1.05 (0.23) 1.03 (0.24) 1.11 (0.26) 
Fibrinogen (g/L, mean (SD)) 3.72 (0.81) 3.64 (0.76) 3.58 (0.74) 
Triglycerides (mmol/L, median (IQR)) 1.84 (1.40–2.38) 1.81 (1.38–2.45) 1.72 (1.34–2.30)
HbA1c (mmol/mol, median (IQR)) 54.1 (46.4‐65.0) 54.6 (46.4‐65.0) 50.8 (42.6‐61.2) 
Plasma creatinine (umol/L, mean (SD)) 83.6 (18.3) 82.8 (16.6) 76.7 (15.4) 
Estimated GFR (mL/min per 1.73 m2, median (IQR)) 80.5 (70.4–95.0) 83.1 (72.2–94.4) 86.6 (75.9–99.4) 
Homocysteine (umol/L, median (IQR)) 10.6 (8.7–13.0) 10.0 (8.4–12.3) 9.5 (7.9–11.3) 
Baseline medication    
Any antithrombotic/anticoagulant  161 (48.3%) 430 (44.7%) 2475 (29.1%) 
Any warfarin 14 (4.2%) 43 (4.5%) 185 (2.2%) 
Aspirin or other antithrombotic (no warfarin) 147 (44.1%) 387 (40.2%) 2290 (26.9%) 
Statin  0 (0.0%)  1 (0.1%)  2 (0.0%) 
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 Stroke (n=333) 
Other CVD event
(n=962) 
No CVD event 
(n=8500) 
Anti‐hypertensive  211 (77.9%)  538 (74.1%)  4095 (75.4%) 
Data are number (%) unless otherwise indicated. 
* P<0.001 between the 3 event groups for all characteristics except metabolic syndrome, LDL cholesterol (both P=0.002), treatment 
group, heart rate, BMI, amputation, total cholesterol, statin and anti-hypertensive (all P>0.05).  
† Missing values at baseline were imputed for homocysteine (273), urinary albumin (27), diabetes duration (17), BMI (7), waist–hip 
ratio (13), fibrinogen (1), urinary creatinine (27), albuminurea (27) 
‡ Normal ACR, <3.5 mg/mmol (men), <2.5 (women);  microalbuminuria,  3.5 -35 (men), 2.5 -25 (women); macroalbuminuria, > 35 
(men), > 25 (women) 
CVD=cardiovascular disease. SD=standard deviation. PTCA=percutaneous transluminal coronary angioplasty. CABG=coronary 
artery bypass grafting. IQR=interquartile range. GFR=glomerular filtration rate. 
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Table 2: Number of strokes during follow-up 
 
Type  First stroke events 
Total stroke 
events 
Number of 
patients* 
Ischaemic stroke 271 299 276 
 Large-artery cerebral infarct 46 52 50 
 Small-artery cerebral infarct 96 108 101 
 Cardioembolic infarct 34 38 36 
 Other causes, or uncertain or unknown   
cause † 
95 101 99 
Haemorrhagic stroke 33 37 37 
 Intracerebral haemorrhage 26 29 29 
 Subarachnoid haemorrhage 7 8 8 
Stroke of unknown pathological type 29 30 29 
Ischaemic  stroke or stroke of unknown 
pathological type 
300 329  302 
Any stroke 333 366 333 
* Some patients had more than one stroke and more than one type of stroke. 
† Included 1 retinal infarction. 
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 Table 3: Results of multivariable analyses for stroke types* 
 
Ischaemic stroke or stroke 
of unknown pathological 
type (302 events) 
Large-artery  
ischaemic stroke (50 events)
Small-artery ischaemic 
stroke (101 events) 
Haemorrhagic stroke 
(37 events) 
  HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Age         
 <60 1  1    1  
 60–65 1.98 (1.41–2.78) <0.001 7.70 (2.26–26.28) 0.001     1.73 (0.56–5.34) 0.34 
 >65 2.35 (1.71–3.23) <0.001 9.52 (2.89–31.31) <0.001     3.33 (1.24–8.92) 0.02 
Sex male 1.72 (1.33–2.24) <0.001     1.64 (1.05–2.55) 0.03     
History of hypertension 1.60 (1.22–2.11) <0.001 2.16 (1.13–4.15) 0.02         
Diabetes duration         
≤2     1    
2–10     1.52 (0.86–2.67) 0.15   
≥10     2.06 (1.15–3.71) 0.02   
Systolic blood pressure (per 15 
mmHg)  1.34 (1.19–1.50) <0.001     1.36 (1.13–1.63) 0.001 1.54 (1.15–2.07) 0.004 
Current smoker 1.52 (1.07–2.18) 0.01     1.78 (1.01–3.14) 0.05     
Prior stroke or TIA 2.06 (1.51–2.80) <0.001     2.51 (1.48–4.26) <0.001 2.80 (1.27–6.20) 0.01 
Prior peripheral vascular disease     2.77 (1.44–5.35) 0.002         
Prior angina, PTCA, or CABG 1.85 (1.43–2.41) <0.001             
History of diabetic retinopathy         1.82 (1.08–3.07) 0.03     
Nephropathy (self-reported or ACR 
measurement) 1.33 (1.05–1.70) 0.02             
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Ischaemic stroke or stroke 
of unknown pathological 
type (302 events) 
Large-artery  
ischaemic stroke (50 events)
Small-artery ischaemic 
stroke (101 events) 
Haemorrhagic stroke 
(37 events) 
  HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
HDL cholesterol (per 0.3 mmol/L)     0.64 (0.46–0.90) 0.01         
LDL cholesterol (per 0.7 mmol/L)  1.14 (1.02–1.27) 0.03      1.30 (1.06–1.58) 0.01     
HbA1c (quartile) (mmol/mol)                
 <43 1        
 43–51 1.64 (1.14–2.36) 0.008             
 >51–62 1.71 (1.18–2.47) 0.004             
 >62 1.82 (1.26–2.63) 0.001             
Fibrinogen (per 0.74 g/L) 1.14 (1.02–1.27) 0.02             
Log homocysteine (per 0.3 (=1 SD 
on log scale)             1.44 (1.09–1.91) 0.01 
* All models were stratified by treatment group. 
 
HR=hazard ratio. TIA= transient ischaemic attack. PTCA=percutaneous transluminal coronary angioplasty. CABG=coronary artery bypass 
grafting. LDL=low-density lipoprotein. HDL=high-density lipoprotein. Hb=hemoglobin. ACR=albumin-creatinine ratio.
13 900 patients screened
4105 excluded
2625 ineligible
1334 withdrew consent
146 other reasons 
333 had a f irst stroke during 
follow-up
271 ischemic strokes
33 hemorrhagic strokes
29 type unknown
679 died
9764 (99.7%) mortality status 
conf irmed at end of  study
9708 (99.1%) morbidity status 
conf irmed at end of  study
9795 randomized
7505 no prior CVD 
1693 prior CVD (excluding 
stroke or TIA)
597 prior stroke or TIA
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